[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Pol
Stanislas
S
Unité d'Hépatologie et Inserm U-370, Hôpital Necker, Paris.
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000635:transmission; D018023:HIV Seronegativity; D006679:HIV Seropositivity; D006526:Hepatitis C / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D015337:Multicenter Studies as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D000637:Transaminases / Q000097:blood
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons; D000637:Transaminases